MORGAN STANLEY PLC/CALL/MODERNA/130/0.1/20.12.24 | Market Closed - Börse Stuttgart 01:20:19 06/07/2024 am IST | ||
| 1.43 EUR | +1.42% |
|
| Current month | +0.70% | ||
| 1 month | -61.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 1.43 | +1.42% |
| 04/24/04 | 1.41 | +6.82% |
| 03/24/03 | 1.32 | -3.65% |
| 02/24/02 | 1.37 | +1.48% |
| 01/24/01 | 1.35 | -4.93% |
Delayed Quote Börse Stuttgart
Last update July 06, 2024 at 01:20 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB40NX |
| ISIN | DE000MB40NX9 |
| Date issued | 28/02/2023 |
| Strike | 130 $ |
| Maturity | 20/12/2024 (167 Days) |
| Parity | 10 : 1 |
| Emission price | 5.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.28 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.09 € |
| Spread % | 5.92% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3
USD
Average target price
145.9
USD
Spread / Average Target
+23.27%
- Stock Market
- Warrants
- Warrant
